Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2012 Sep;12(9):1173-90. doi: 10.1517/14712598.2012.693472. Epub 2012 Jun 1.

Using antibodies to target cancer therapeutics.

Author information

  • 1Center for Molecular Medicine and Immunology, 300 The American Road, Morris Plains, NJ 07950, USA.



Over a half a century ago, radiolabeled antibodies were shown to localize selectively in tissues based on the expression of unique antigens. Antibodies have since become the de facto targeting agent, even inspiring the development of non-antibody compounds for targeting purposes.


In this article, we review various aspects of how antibodies are transforming the way cancer is being detected and treated, with the growing demand for unconjugated and many new antibody conjugates. While unconjugated antibodies continue to garner most of the attention, interest in new antibody drug conjugates and immunotoxins has expanded over the past few years. However, there continues to be active research with new radioimmunoconjugates for imaging and therapy, particularly with α-emitters, as well as antibody-targeted cytokines and other biological response modifiers.


The increasing number of new agents being developed and tested clinically suggests that antibody-targeted compounds will have an expanding role in the future.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk